UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000014116
Receipt number R000016430
Scientific Title Study of effects on the retina morphological changes and vision of Aflibercept intravitreal injection in patients with macular edema due to central retinal vein occlusion.
Date of disclosure of the study information 2014/06/14
Last modified on 2019/03/15 11:11:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of effects on the retina morphological changes and vision of Aflibercept intravitreal injection in patients with macular edema due to central retinal vein occlusion.

Acronym

Study of effects of Aflibercept in patients with macular edema due to central retinal vein occlusion.

Scientific Title

Study of effects on the retina morphological changes and vision of Aflibercept intravitreal injection in patients with macular edema due to central retinal vein occlusion.

Scientific Title:Acronym

Study of effects of Aflibercept in patients with macular edema due to central retinal vein occlusion.

Region

Japan


Condition

Condition

For recurrent or persistent macular edema due to central retinal vein occlusion of the following anti

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Aflibercept intravitreal injection, central retinal thickness, foveal choroidal thickness, exudative changes, retinal blood flow to observe the effect on the change

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1.The improvement rate of best corrected visual acuity at six months after the Aflibercept injection.
2.Presence or absence of exudative change, the changes of central retinal thickness and foveal choroidal thickness by OCT at 6 and 12 months after the Aflibercept injection.

Key secondary outcomes

1.The retinal blood flow changes measureed by LSFG at 6 and 12 months after the Aflibercept injection.
2.Duration from Aflibercept injection to recurrence.
3.Adverse event


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Intravitreal administration of Aflibercept(Genetical Recombination)(EYLEA)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Patients with macular edema due to central retinal vein occlusion.
2.Central retinal thickness-=>250&micro;m
3.Point visual acuity less than 0.9
4.Patients who had received treatment with bevacizumab or ranibizumab for macular edema due to central retinal vein occlusion.
5.Age of patients 20years of age or older at the time of acquisition agreement.
6.After receiving a sufficient explanation upon participation in this study,on a full understanding,patients who obtained the document voluntary consent of the patient himself

Key exclusion criteria

1.Patients who underwent the pan-retinal photocoagulation within 3 months.
2.Patients who underwent photocoagulation treatment for macular edema within 3 months.
3.Patients treated with steroids to intraocular within 3 months.
4.The patients with a history of hypersensitivity to the study drug.
5.Patients who developed heart and cerebrovascular disease severe within 6 months.
6.Patients attending physician was deemed inappropriate as a subject.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takashi Kitaoka

Organization

Nagasaki University Hospital

Division name

Ophthalmology

Zip code


Address

1-7-1 Sakamoto,Nagasaki

TEL

095-819-7345

Email

tkitaoka@nagasaki-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Makiko Matsumoto

Organization

Nagasaki University Hospital

Division name

Ophthalmology

Zip code


Address

1-7-1 Sakamoto,Nagasaki

TEL

095-819-7345

Homepage URL


Email

makimaki@nagasaki-u.ac.jp


Sponsor or person

Institute

Nagasaki University Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 06 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 05 Month 01 Day

Date of IRB

2014 Year 03 Month 25 Day

Anticipated trial start date

2014 Year 06 Month 16 Day

Last follow-up date

2018 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 05 Month 30 Day

Last modified on

2019 Year 03 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016430


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name